Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma

University Hospitals Cleveland Medical Center press statement

Key clinical point: A phase 1 trial of CAR T therapy is enrolling adult patients with NHL who have not responded to standard therapies.

Major finding: The trial site has the ability to manufacture the cells on site, saving patients time.

Study details: A phase 1 trial to evaluate safety.

Disclosures: The study will be funded by University Hospitals Seidman Cancer Center.

Read the article.

Citation:

University Hospitals Cleveland Medical Center press statement

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Aggressive Lymphomas

Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025